SN
Sanjay Nayak
Chief Strategy Officer

Sanjay Nayak insider trades: Ocular Therapeutix (OCUL) stock sales

Chief Strategy Officer, Ocular Therapeutix Last trade Aug 24, 2026 14 Form 4 filings
$166K
Sold, last 12 months
5 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2024
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Sanjay reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 24, 2026OCUL↓ Sell$20K
May 26, 2026OCUL↓ Sell$15K
Feb 23, 2026OCUL↓ Sell$15K
Feb 12, 2026OCUL↓ Sell$94K
Nov 24, 2025OCUL↓ Sell$23K
Aug 25, 2025OCUL↓ Sell$23K
May 23, 2025OCUL↓ Sell$13K
Feb 24, 2025OCUL↓ Sell$13K
Nov 25, 2024OCUL↓ Sell$16K
Aug 23, 2024OCUL↓ Sell$17K
May 23, 2024OCUL↓ Sell$13K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other OCUL insiders

Open-market trades in the last 12 months

About Sanjay Nayak's insider trades

Sanjay Nayak is Chief Strategy Officer at Ocular Therapeutix (OCUL). Since May 23, 2024, Sanjay has reported no open-market purchases and 11 sales worth $262K on SEC Form 4. In the last 12 months: 5 sales ($166K).

Their filings also include grants and awards (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OCUL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.